MediWound (NASDAQ:MDWD) Upgraded at StockNews.com

StockNews.com upgraded shares of MediWound (NASDAQ:MDWD) to a sell rating in a research report report published on Friday.

A number of other equities research analysts have also recently issued reports on MDWD. Craig Hallum initiated coverage on shares of MediWound in a report on Friday, February 28th. They issued a “buy” rating and a $39.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of MediWound in a research report on Thursday.

MediWound Price Performance

NASDAQ MDWD opened at $16.27 on Friday. The firm has a market capitalization of $175.60 million, a PE ratio of -5.61 and a beta of 0.82. MediWound has a 12 month low of $12.78 and a 12 month high of $24.00. The company’s 50 day simple moving average is $18.17 and its 200 day simple moving average is $17.59.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings data on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.23. The firm had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.79 million. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same quarter last year, the business posted ($0.19) EPS. Sell-side analysts anticipate that MediWound will post -2.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MediWound

Several hedge funds have recently bought and sold shares of the company. State Street Corp raised its holdings in shares of MediWound by 219.6% during the third quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock worth $1,197,000 after acquiring an additional 45,529 shares during the period. Barclays PLC boosted its holdings in shares of MediWound by 311.3% during the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 8,449 shares during the period. Rhumbline Advisers raised its stake in MediWound by 7.3% in the 4th quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company’s stock worth $193,000 after purchasing an additional 739 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of MediWound in the 3rd quarter valued at approximately $212,000. Finally, Essex Investment Management Co. LLC raised its position in shares of MediWound by 30.7% in the 4th quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company’s stock valued at $2,651,000 after buying an additional 35,012 shares in the last quarter. 46.83% of the stock is currently owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.